Big Pharma ally Atreca scoops $35M as I-O assets near IND

Atreca has raised $35 million. The series B tees up Atreca to pick its first clinical candidate derived from a platform that has attracted the interest of a who’s who of Big Pharma players. 

New investor Wellington Management co-led the round with the anonymous U.S. healthcare fund that drove Atreca to a $56 million series A in 2015. Atreca funneled that money into its preclinical research programs. And, by the time Atreca picked up its Fierce 15 award 11 months ago, it had set its sights on filing an IND in 2018.

Redwood City, California-based Atreca has now refueled to continue its discovery efforts while stepping up its push into development. Management plans to pick a clinical candidate from its lead oncology program by the end of the year.

Read the article at Fierce Biotech